Wed, August 10, 2022

Gena Wang Maintained (ARCT) at Sell with Decreased Target to $16 on, Aug 10th, 2022

Gena Wang of Barclays, Maintained "Arcturus Therapeutics Holdings Inc." (ARCT) at Sell with Decreased Target from $17 to $16 on, Aug 10th, 2022.

Gena has made no other calls on ARCT in the last 4 months.



There are 4 other peers that have a rating on ARCT. Out of the 4 peers that are also analyzing ARCT, 2 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Joel Beatty of "Baird" Upgraded from Sell to Hold and Decreased Target to $18 on, Wednesday, May 11th, 2022
  • Ed Arce of "HC Wainwright & Co." Maintained at Hold with Decreased Target to $19 on, Tuesday, May 10th, 2022


These are the ratings of the 2 analyists that currently disagree with Gena


  • Pete Stravropoulos of "Cantor Fitzgerald" Initiated at Buy and Held Target at $39 on, Tuesday, July 19th, 2022
  • Madhu Kumar of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $8 on, Tuesday, May 24th, 2022